NEW YORK (GenomeWeb News) – Atossa Genetics today said into has signed a nationwide agreement with preferred provider organization HealthSmart.

The agreement, the Seattle-based breast cancer diagnostic firm said, is to provide patients in HealthSmart's network greater access to Atossa's ForeCyte Breast Health Test. The risk stratification test for breast cancer is based on Atossa's US Food and Drug Administration-cleared Mammary Aspirate Specimen Cytology Test System, or MASCT.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.